General Information
Drug ID
DR00140
Drug Name
Ezetimibe
Synonyms
(-)-Sch 58235; (1-(4-fluorophenyl)-(3R)-(3-(4-fluorophenyl)-(3S)-hydroxypropyl)-(4S)-(4-hydroxyphenyl)-2-azetidinone); (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one; (3R,4S)-1-(p-Fluorophenyl)-3-((3S)-3-(p-fluorophenyl)-3-hydroxypropyl)-4-(p-hydroxyphenyl)-2-azetidinone; 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-(4-hydroxyphenyl)-2-azetidione; 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone; Essex brand of ezetimibe; Ezedoc; Ezetimib; Ezetimibe (JAN/USAN/INN); Ezetimibe [USAN:INN]; Ezetrol; Inegy (TN); MK-0653; MSD brand of ezetimibe; Merck brand of ezetimibe; SCH-58235; SCH58235; Sch 58235; Schering-Plough brand of ezetimibe; Vytorin (TN); Zetia; Zetia (TN); Zetia , Ezetrol, Ezetimibe; Zient
Drug Type
Small molecular drug
Indication Hypercholesterolemia [ICD11: 5C80.0] Approved [1]
Therapeutic Class
Anticholesteremic Agents
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=150311"></iframe>
3D MOL 2D MOL
Formula
C24H21F2NO3
Canonical SMILES
C1=CC(=CC=C1C2C(C(=O)N2C3=CC=C(C=C3)F)CCC(C4=CC=C(C=C4)F)O)O
InChI
InChI=1S/C24H21F2NO3/c25-17-5-1-15(2-6-17)22(29)14-13-21-23(16-3-11-20(28)12-4-16)27(24(21)30)19-9-7-18(26)8-10-19/h1-12,21-23,28-29H,13-14H2/t21-,22+,23-/m1/s1
InChIKey
OLNTVTPDXPETLC-XPWALMASSA-N
CAS Number
CAS 163222-33-1
Pharmaceutical Properties Molecular Weight 409.433 Topological Polar Surface Area 60.8
Heavy Atom Count 30 Rotatable Bond Count 6
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 5
PubChem CID
150311
PubChem SID
10250673 , 103326446 , 104179182 , 104253290 , 104428106 , 11528896 , 117884262 , 12014979 , 124658886 , 124757411 , 124801398 , 125164215 , 126592989 , 126621626 , 126653456 , 126667079 , 127315811 , 127315812 , 127315813 , 127315814 , 127315815 , 127315816 , 127315817 , 127315818 , 127315819 , 127315820 , 127315821 , 127315822 , 127315823 , 127315824 , 128826430 , 131854738 , 134338005 , 135107180 , 14879623 , 14928749 , 26719841 , 46226990 , 46386640 , 46507625 , 49681809 , 49693660 , 50539938 , 53787196 , 57347010 , 71821424 , 7849028 , 81146074 , 92308446 , 92718207
ChEBI ID
ChEBI:49040
TTD Drug ID
D09LWS
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
BSEP Transporter Info Bile salt export pump Substrate [3]
MRP2 Transporter Info Multidrug resistance-associated protein 2 Substrate [4]
MRP3 Transporter Info Multidrug resistance-associated protein 3 Substrate [2]
OATP1B1 Transporter Info Organic anion transporting polypeptide 1B1 Substrate [5]
P-GP Transporter Info P-glycoprotein 1 Substrate [6]
References
1 Ezetimibe was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Complex pharmacokinetic behavior of ezetimibe depends on abcc2, abcc3, and abcg2. Drug Metab Dispos. 2009 Aug;37(8):1698-702.
3 Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
4 Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin Pharmacol Ther. 2006 Mar;79(3):206-17.
5 A LC-MS/MS method to quantify the novel cholesterol lowering drug ezetimibe in human serum, urine and feces in healthy subjects genotyped for SLCO1B1. J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Jan 2;830(1):143-50.
6 Pharmacokinetic and pharmacodynamic interactions between the immunosuppressant sirolimus and the lipid-lowering drug ezetimibe in healthy volunteers. Clin Pharmacol Ther. 2010 Jun;87(6):663-7.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.